卡培他濱維持治療在晚期三陰性乳腺癌中的生存獲益分析
DOI:10.16424/j.cnki.cn32-1807/r.2025.04.004
[關(guān)鍵詞]晚期乳腺癌;卡培他濱;腫瘤標(biāo)志物;炎癥反應(yīng);免疫功能 [中圖分類號]R737.9 [文獻(xiàn)標(biāo)志碼]A [文章編號] 1674-7887(2025)04-0327-05
Survival benefitanalysisof capecitabinemaintenance therapyin advanced triple-negative breast cancer*
XUTonglin**,SHAO Qi2*** (204 (Departmentof Thyroid and Breast Surgery,Affiliated NantongHospital 3of Nantong University,Jiangsu 226OO6; 2Department of Chemotherapy,Afiliated Hospital of Nantong University)
[Abstract]Objective:Toinvestigate thesurvival benefitsofcapecitabinemaintenance therapyinadvancd triple-negative breastcancer.Methods:Seventycasesof advanced triple-negativebreastcancerinAfiliated Hospitalof Nantong University fromJanuary2020toJanuary2O22 werecollctedanddividedintocontrolgroup(TXchemotherapyregimen)andobservation group(TXchemotherapyregimen+capecitabinemaintenance therapy)accrding todiferenttreatmentregiments.Theclinical efcacyof thetwogroupswascompared,andthelevelsofserumtumormarkers,inflammatoryesponseindicators,mmune function indicators,adversereactionsandsurvivalafter24monthsoffollow-upweredetected.Results:Theefectofobservation group was better than that of control group( P <0.05).After treatment, the levels of tumor markers and inflammatory factors were decreased inboth groupscompared with before treatment,andthelevels werelower inobservation group(P 0.05).After 24 months of follow-up,the survival was 22 cases(62.86 % ) in the observation group and 12 cases(34.29 % ) in the control group,and the difference in 24- month survival rate between the two groups was statistically significant(Log-rank χ2 =6.555, P<0.05 ).Conclusion: Capecitabine maintenance therapycannotonlyeffctivelyreduce the levelof serum tumor markersandbutalso improve inflammatory response,theimmune functionand prognosisof patientswithadvanced triple-negative breastcancer,and hasacertainsafety. [Key Words]advanced breast cancer; capecitabine; tumor markers; inflammatory response; immune function
乳腺癌作為女性常見惡性腫瘤,其臨床通常表現(xiàn)為乳房腫塊、皮膚改變、乳頭回縮、溢液等癥狀。(剩余8421字)
-
-
- 南通大學(xué)學(xué)報(醫(yī)學(xué)版)
- 2025年04期
- CRS-R結(jié)合腦電功率譜模型在...
- 年齡和高血壓分層的同型半胱氨酸...
- 影響孤獨癥主要照護(hù)者抑郁心理及...
- 卡培他濱維持治療在晚期三陰性乳...
- 基于冠狀動脈造影的影像組學(xué)列線...
- bFSH與不孕女性輔助生殖助孕...
- 丙泊酚與依托咪酯對婦科腹腔鏡手...
- 2020—2023年南通地區(qū)新...
- 子宮動脈栓塞術(shù)聯(lián)合清宮術(shù)對比甲...
- 健康體檢的中老年人肌少癥相關(guān)預(yù)...
- 急性氨影響副溶血弧菌的基因表達(dá)...
- 中性粒細(xì)胞與淋巴細(xì)胞比值評估急...
- 腹腔鏡下腹膜外間隙內(nèi)環(huán)口縮窄結(jié)...
- DNA錯配修復(fù)蛋白在早期胃腺癌...
- SMILE手術(shù)對青壯年近視患者...
- 人口和臨床特征對精神分裂癥患者...
- 激光在根管消毒中的相關(guān)研究進(jìn)展...
- 基于陰陽自和理論探討Treg/...
- 低頻重復(fù)經(jīng)顱磁刺激聯(lián)合正念認(rèn)知...
- 膀胱容量對宮頸癌精確放療擺位誤...
- 面下部重塑微整形術(shù)期間應(yīng)用玻尿...